Navigation Links
Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
Date:9/23/2008

xin which shuts down protein production in the cancer cells."

"It worked well in our cell culture models and now we are moving into pre-clinical experiments," Brody says.

The agent will not attack normal cells because the molecular machinery needed to turn on mesothelin is not found in normal cells, Brody says. Additionally, Sawicki has modified the diphtheria DNA to ensure that toxin that might be released from dying cancer cells is not taken up by healthy, normal cells.

But the researchers are now perfecting even more stringent measures to ensure safety, he says. "We can't help being hopeful," he says. "Our findings suggest that such a strategy will work in the clinical setting against the majority of pancreatic tumors."


'/>"/>

Contact: Ed Federico
ed.federico@jefferson.edu
Thomas Jefferson University
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Jefferson receives $11.6M NIH grant to study novel mechanisms of heart failure
2. Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma patients
3. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
4. ESA trains next generation of atmospheric scientists
5. Scientists find redesigned hammer that forged evolution of pregnancy in mammals
6. Scientists discover a new Pacific iguana
7. Scientists identify the genes that cause blindness produced by corneal edema
8. UNC scientists turn human skin cells into insulin-producing cells
9. Scientists isolate cancer stem cells
10. Scientists form alliance to develop nanotoxicology protocols
11. Scientists point to forests for carbon storage solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- MODA Technology Partners, a global software company ... testing for the Pharmaceutical industry, today announced the ... generation mobile data acquisition platform. The latest release ... their regulated manufacturing processes. ,, MODA 3.0 ... Fully-Configurable Test Methods: Each test method in ...
(Date:12/13/2009)... have resolved a question about how a popular ... using biosensors that reveal previously hidden components of ... delusions and hallucinations characterize the illness, people with ... information in a particular order, difficulties that interfere ... function well, said Lee Schroeder, a student in ...
(Date:12/13/2009)... 2009Researchers at The Scripps Research Institute have solved ... from an ancient family of enzymes can have ... addition to providing guidance for understanding other molecules ... underpinning for the protein,s possible use for combating ... research was published in the December 13, 2009 ...
Breaking Biology News(10 mins):MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Scripps Research scientists crack mystery of protein's dual function 2Scripps Research scientists crack mystery of protein's dual function 3Access Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Healthcare Conference 13766 1Access Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Healthcare Conference 13766 2Access Pharmaceuticals to Present at the Rodman 26 Renshaw Annual Healthcare Conference 13766 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 1LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 4LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 5Thoratec Presentation at Baird Conference to be Webcast 13764 1
... is the shape of the cochlea the snail-shell-shaped organ ... impulses that the brain deciphers which proves to be ... the Proceedings of the National Academy of Sciences establishes a ... limit of more than a dozen different mammals. , The ...
... of patients around the world following a routine dosage ... a frantic search to uncover what could make the ... Institute was among a small group of scientists with ... the source of the contamination. , Robert J. ...
... May Enable Food-Borne Pathogens on Leafy Vegetables ... sequester harmful food-borne pathogens ultimately contributing to their ... Technological University, Cookeville and the Produce Safety and ... their findings in the April 2008 issue of ...
Other Biology News:Study links low-frequency hearing to shape of the cochlea 2Study links low-frequency hearing to shape of the cochlea 3Study links low-frequency hearing to shape of the cochlea 4Deadly dose: Rensselaer heparin expert helps uncover source of lethal contamination 2Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Tips from the Journals of the American Society for Microbiology 4
(Date:12/14/2009)... Colo. and THOUSAND OAKS, Calif., Dec. 14 /PRNewswire-FirstCall/ ... and Amgen Inc.(Nasdaq: AMGN ) today announced ... exclusive worldwide rights to Array,s small-molecule glucokinase activator ... Phase 1 clinical trial in patients with Type ... of the agreement, Array will receive an upfront ...
(Date:12/14/2009)... N.J., Dec. 14 The third edition ... , published by the Infusion ... treatment for anthracycline extravasation.(1) Anthracyclines are a ... and epirubicin that have been used in the ... early 1970s.(2) ,, According to the ...
(Date:12/14/2009)... Dec. 14 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that, owing to ... fibrillation drug market will increase more than sevenfold ... in 2018 in the United States, France, Germany, ... The new Pharmacor report entitled Atrial Fibrillation ...
(Date:12/11/2009)... SEATTLE, Dec. 11 Dendreon Corporation (Nasdaq: ... of its previously announced public offering have exercised ... 2,250,000 shares of common stock at the public ... exercise of the option increases the size of ... of common stock. Dendreon expects to receive ...
Breaking Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... RiverVest Venture Partners,announced today that it has completed ... L.P., with total committed capital of $75,million from ... a Small Business Investment Company, had total private ... from the Small Business Administration., RiverVest co-founder ...
... Jersey, April 11, Rosetta Genomics Ltd. (Nasdaq: ROSG ... and therapeutics, announced,today it will present multiple posters ... The posters will include data on Rosetta Genomics,unique ... to develop,objective and standardized diagnostic tests and therapeutics ...
... 11, 2008 In the event of an outbreak ... changes responsible for virulence or drug resistance is essential ... and analysis of a pathogen genome is time-intensive and ... now developed a comparative genomics strategy to drastically reduce ...
Other Biology Technology:RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 2RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing 2
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... automates the denaturation and hybridization steps in ... for clinical and research personnel. The low ... sample types, is easy to use, and ... while ensuring overall precision and accuracy in ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... Iodide (PI) is a fluorescent nucleic acid ... acids. As a nuclear counterstain, propidium ... red in color. The fluorescent red ... blue fluorochromes such as FITC, Cy2 or ...
Biology Products: